Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026

Sponsored bySen. Murkowski, Lisa [R-AK]AK· Introduced 30 avril 2026

Open on Congress.gov

Cosponsors

Actions

Amendments

Committees

—

Since introduced

Introduced

Committee

Passed Chamber

Passed Both

Enacted

Step 0 of 0

Latest action

Held at the desk.

10 août 2026·2 days ago

Summary

Reported to Senate · Updated 27 juillet 2026

Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026

This bill reauthorizes through FY2031 and revises programs that support research and development of drugs and other therapies to address amyotrophic lateral sclerosis (also known as ALS or Lou Gehrig's disease) and other neurodegenerative diseases.

The bill reauthorizes

grants from the National Institutes of Health (NIH) for scientific research on investigational drugs to prevent or treat ALS for individuals not otherwise eligible for clinical trials,
grants from the Food and Drug Administration (FDA) for research and development of therapies to prevent and treat ALS and other neurodegenerative diseases, and
a Public-Private Partnership including the FDA and NIH that supports development and regulatory review of treatments for neurodegenerative diseases.

Also, the bill revises the NIH grants to require (1) the NIH, in considering grant renewal, to assess available information on the safety and efficacy of the investigational drugs; (2) grantees to promptly report available safety data from ongoing clinical trials; and (3) the NIH to determine the timeframe for enrollment in clinical trials for the investigational drugs.

Additionally, every five years, the FDA must publish a plan describing actions it will take over a five-year period to foster development of safe and effective drugs, and facilitate access to investigational drugs, for ALS and other rare neurodegenerative diseases. Each plan must include the FDA's previous actions and recommendations for improvements.

Finally, the Government Accountability Office and the Department of Health and Human Services must report on the impacts of these grants.

Timeline

11 actions

Received in the House.
10 août 2026 · Floor
Held at the desk.
10 août 2026 · Floor
Message on Senate action sent to the House.
10 août 2026 · Floor
Passed Senate with an amendment by Voice Vote. (consideration: CR S4425-4426; text: CR S4425-4426)
4 août 2026 · Floor
Passed/agreed to in Senate: Passed Senate with an amendment by Voice Vote.
4 août 2026 · Floor
Passed/agreed to in Senate: Passed Senate with an amendment by Voice Vote.
4 août 2026 · Floor
Passed Senate with an amendment by Voice Vote. (consideration: CR S4425-4426; text: CR S4425-4426)
4 août 2026 · Floor
Committee on Health, Education, Labor, and Pensions. Reported by Senator Cassidy with an amendment in the nature of a substitute. Without written report.
16 juillet 2026 · Committee
Committee on Health, Education, Labor, and Pensions. Reported by Senator Cassidy with an amendment in the nature of a substitute. Without written report.
16 juillet 2026 · Committee
Committee on Health, Education, Labor, and Pensions. Reported by Senator Cassidy with an amendment in the nature of a substitute. Without written report.
16 juillet 2026 · Committee
Committee on Health, Education, Labor, and Pensions. Reported by Senator Cassidy with an amendment in the nature of a substitute. Without written report.
16 juillet 2026 · Committee
Placed on Senate Legislative Calendar under General Orders. Calendar No. 461.
16 juillet 2026 · Calendars
Committee on Health, Education, Labor, and Pensions. Reported by Senator Cassidy with an amendment in the nature of a substitute. Without written report.
16 juillet 2026 · Committee
Placed on Senate Legislative Calendar under General Orders. Calendar No. 461.
16 juillet 2026 · Calendars
Committee on Health, Education, Labor, and Pensions. Reported by Senator Cassidy with an amendment in the nature of a substitute. Without written report.
16 juillet 2026 · Committee
Committee on Health, Education, Labor, and Pensions. Ordered to be reported with an amendment in the nature of a substitute favorably.
17 juin 2026 · Committee
Committee on Health, Education, Labor, and Pensions. Ordered to be reported with an amendment in the nature of a substitute favorably.
17 juin 2026 · Committee
Committee on Health, Education, Labor, and Pensions. Ordered to be reported with an amendment in the nature of a substitute favorably.
17 juin 2026 · Committee
Committee on Health, Education, Labor, and Pensions. Ordered to be reported with an amendment in the nature of a substitute favorably.
17 juin 2026 · Committee
Introduced in Senate
30 avril 2026 · IntroReferral

Sponsorship

15 cosponsors

Sponsor

Sen. Murkowski, Lisa [R-AK]AK

Cosponsors

Democrat853%
Republican747%

Democrat:Sen. Whitehouse, Sheldon [D-RI]RI
Republican:Sen. Barrasso, John [R-WY]WY
Democrat:Sen. Merkley, Jeff [D-OR]OR
Republican:Sen. McCormick, David [R-PA]PA
Democrat:Sen. Markey, Edward J. [D-MA]MA
Republican:Sen. Daines, Steve [R-MT]MT
Democrat:Sen. Hassan, Margaret Wood [D-NH]NH
Democrat:Sen. Gillibrand, Kirsten E. [D-NY]NY
Republican:Sen. Curtis, John R. [R-UT]UT
Republican:Sen. Banks, Jim [R-IN]IN
Republican:Sen. Capito, Shelley Moore [R-WV]WV
Democrat:Sen. Padilla, Alex [D-CA]CA
Republican:Sen. Collins, Susan M. [R-ME]ME
Democrat:Sen. Klobuchar, Amy [D-MN]MN
Democrat:Sen. Coons, Christopher A. [D-DE]DE

Classification

Policy area

Health

Committees

Health, Education, Labor, and Pensions Committee
Senate · Standing
- Referred To30 Apr 2026
- Markup By17 Jun 2026
- Reported By16 Jul 2026

Cosponsor momentum

Cumulative over time

Track Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026 as it moves through Congress